{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:57:27Z","timestamp":1790567847082,"version":"4.1.0"},"reference-count":36,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Using LYmphoma Study Association clinical trials combining 438 first\u2010line large B\u2010cell lymphomas (LBCL) patients &gt;80\u2009years old, we defined SENIOR\u2010IPI, an easily applicable prognostic index for this elderly population treated with an anti\u2010CD20\u2010miniCHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)\u2010based regimen. SENIOR\u2010International Prognostic Index (SENIOR\u2010IPI) takes into account accessible variables (number of aaIPI predictors, lactate dehydrogenase &gt; 3x Upper Limit of Normal (LDH &gt;3\u00d7 ULN), albumin &lt;35\u2009g\/L and number of years over 80) and segregates patients into four risk categories. In the training cohort, SENIOR\u2010IPI performed better than IPI, age\u2010adjusted IPI (aaIPI)\u00a0and National Comprehensive Cancer Network IPI (NCCN\u2010IPI) for progression\u2010free survival (PFS) and overall survival (OS). The validation cohort included 195 patients from the real\u2010world REal world all dAta in LYmphoma and Survival in Adults (REALYSA) cohort and confirmed better performance of SENIOR\u2010IPI than IPI, aaIPI and NCCN\u2010IPI both for PFS (\n                    <jats:italic>C<\/jats:italic>\n                    \u2010index 0.66 vs. 0.61, 0.64 and 0.61 respectively) and OS (\n                    <jats:italic>C<\/jats:italic>\n                    \u2010index 0.67 vs. 0.59, 0.62 and 0.61 respectively). Restricted mean survival times at 2 and 5\u2009years were also evaluated: at 2\u2009years, 10 additional SENIOR\u2010IPI points led to 3.7 and 3.6\u2009months of survival lost, respectively, in the training and validation cohorts. Overall, SENIOR\u2010IPI is an easily applicable and reproducible prognostic index, using only readily available clinical and biological data, which better stratifies prognosis of LBCL patients &gt;80\u2009years old fit for age\u2010adapted immunochemotherapy than IPI, aaIPI and NCCN\u2010IPI.\n                  <\/jats:p>","DOI":"10.1111\/bjh.70784","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:47:06Z","timestamp":1790567226000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["<scp>SENIOR<\/scp>\n                    \u2010\n                    <scp>IPI<\/scp>\n                    : An easily applicable prognostic index for first\u2010line large B\u2010cell lymphomas patients &gt;80\u2009years treated with curative intent"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0109-6820","authenticated-orcid":false,"given":"Sydney","family":"Dubois","sequence":"first","affiliation":[{"name":"Department of Hematology Centre Henri Becquerel  Rouen France"},{"name":"Inserm U1245, UNIROUEN University of Normandie  Rouen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Cherblanc","sequence":"additional","affiliation":[{"name":"Lymphoma Academic Research Organisation  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelien","family":"Belot","sequence":"additional","affiliation":[{"name":"Lymphoma Academic Research Organisation  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0039-1983","authenticated-orcid":false,"given":"Lucie","family":"Oberic","sequence":"additional","affiliation":[{"name":"Hematology Department IUCT\u2014Oncopole  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3131-3718","authenticated-orcid":false,"given":"Herv\u00e9","family":"Ghesqui\u00e8res","sequence":"additional","affiliation":[{"name":"Department of Hematology Centre Hospitalier Lyon\u2010Sud, Hospices Civils de Lyon, Universit\u00e9 Claude Bernard Lyon 1  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Department Henri Mondor University Hospital, AP\u2010HP  Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7022-5246","authenticated-orcid":false,"given":"Herv\u00e9","family":"Tilly","sequence":"additional","affiliation":[{"name":"Department of Hematology Centre Henri Becquerel  Rouen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0708-8776","authenticated-orcid":false,"given":"Jean\u2010Philippe","family":"Jais","sequence":"additional","affiliation":[{"name":"Biostatistics Unit Imagine Institut Inserm UMR 11 63, H\u00f4pital Necker\u2010Enfants Malades  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6804-7943","authenticated-orcid":false,"given":"Fabrice","family":"Jardin","sequence":"additional","affiliation":[{"name":"Department of Hematology Centre Henri Becquerel  Rouen France"},{"name":"Inserm U1245, UNIROUEN University of Normandie  Rouen France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,27]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio R","year":"2022","journal-title":"Leukemia"},{"key":"e_1_2_11_3_1","unstructured":"Surveillance Epidemiology and End Results Program.SEER. Available from:https:\/\/seer.cancer.gov\/index.html"},{"key":"e_1_2_11_4_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","article-title":"Epidemiology of diffuse large B\u2010cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population\u2010level projections for 2020\u20102025","volume":"63","author":"Kanas G","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_11_5_1","volume-title":"U.S. Census Bureau, International Population Reports, P95\/16\u20101, An aging world: 2015","author":"He W","year":"2016"},{"key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1080\/10428194.2018.1443332","article-title":"Frontline treatment of diffuse large B\u2010cell lymphoma in elderly: a systematic review of clinical trials in post\u2010rituximab era","volume":"59","author":"Beygi S","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_11_7_1","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R\u2010IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B\u2010cell lymphoma treated with R\u2010CHOP","volume":"109","author":"Sehn LH","year":"2007","journal-title":"Blood"},{"key":"e_1_2_11_8_1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced international prognostic index (NCCN\u2010IPI) for patients with diffuse large B\u2010cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou Z","year":"2014","journal-title":"Blood"},{"key":"e_1_2_11_9_1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjh.13116","article-title":"A modified scoring of the NCCN\u2010IPI is more accurate in the elderly and is improved by albumin and \u03b22\u2010microglobulin","volume":"168","author":"Melchardt T","year":"2015","journal-title":"Br J Haematol"},{"key":"e_1_2_11_10_1","first-page":"433","article-title":"Validation of prognostic models in elderly patients with diffuse large B\u2010cell lymphoma in a real\u2010world nationwide population\u2010based study \u2013 development of a clinical nomogram","volume":"104","author":"Jelicic J","year":"2025","journal-title":"Ann Hematol"},{"key":"e_1_2_11_11_1","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.20.02465","article-title":"Simplified geriatric assessment in older patients with diffuse large B\u2010cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi","volume":"39","author":"Merli F","year":"2021","journal-title":"J Clin Oncol"},{"key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.3324\/haematol.2022.282289","article-title":"The geriatric prognostic index: a clinical prediction model for survival of older diffuse large B\u2010cell lymphoma patients treated with standard immunochemotherapy","volume":"108","author":"Isaksen KT","year":"2023","journal-title":"Haematologica"},{"key":"e_1_2_11_13_1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R\u2010miniCHOP) in elderly patients older than 80\u2009years with diffuse large B\u2010cell lymphoma: a multicentre, single\u2010arm, phase 2 trial","volume":"12","author":"Peyrade F","year":"2011","journal-title":"Lancet Oncol"},{"key":"e_1_2_11_14_1","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2352-3026(16)30171-5","article-title":"Combination of ofatumumab and reduced\u2010dose CHOP for diffuse large B\u2010cell lymphomas in patients aged 80\u2009years or older: an open\u2010label, multicentre, single\u2010arm, phase 2 trial from the LYSA group","volume":"4","author":"Peyrade F","year":"2017","journal-title":"Lancet Haematol"},{"key":"e_1_2_11_15_1","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1200\/JCO.20.02666","article-title":"Subcutaneous rituximab\u2010MiniCHOP compared with subcutaneous rituximab\u2010MiniCHOP plus lenalidomide in diffuse large B\u2010cell lymphoma for patients age 80\u2009years or older","volume":"39","author":"Oberic L","year":"2021","journal-title":"J Clin Oncol"},{"key":"e_1_2_11_16_1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/s12889-021-10433-4","article-title":"A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the \u201cREal world dAta in LYmphoma and survival in adults\u201d (REALYSA) cohort","volume":"21","author":"Ghesqui\u00e8res H","year":"2021","journal-title":"BMC Public Health"},{"key":"e_1_2_11_17_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v045.i03","article-title":"Mice: multivariate imputation by chained equations in R","volume":"45","author":"Buuren SV","year":"2011","journal-title":"J Stat Softw"},{"key":"e_1_2_11_18_1","first-page":"1065","article-title":"Large\u2010sample significance levels from multiply imputed data using moment\u2010based statistics and an F reference distribution","volume":"86","author":"Li KH","year":"1991","journal-title":"J Am Stat Assoc"},{"key":"e_1_2_11_19_1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.1991.9.1.191","article-title":"Median follow\u2010up in clinical trials","volume":"9","author":"Shuster JJ","year":"1991","journal-title":"J Clin Oncol"},{"key":"e_1_2_11_20_1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/sim.6370","article-title":"Comparing two correlated C indices with right\u2010censored survival outcome: a one\u2010shot nonparametric approach","volume":"34","author":"Kang L","year":"2015","journal-title":"Stat Med"},{"key":"e_1_2_11_21_1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/M22-0844","article-title":"Assessing performance and clinical usefulness in prediction models with survival outcomes: practical guidance for Cox proportional hazards models","volume":"176","author":"McLernon DJ","year":"2023","journal-title":"Ann Intern Med"},{"key":"e_1_2_11_22_1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.cmpb.2007.11.017","article-title":"SAS and R functions to compute pseudo\u2010values for censored data regression","volume":"89","author":"Klein JP","year":"2008","journal-title":"Comput Methods Programs Biomed"},{"key":"e_1_2_11_23_1","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood-2025-786","article-title":"Optimizing risk stratification in patients aged 80+ years with large B\u2010cell lymphoma: comparison of prognostic indices in three pooled international cohorts","volume":"146","author":"Vodicka P","year":"2025","journal-title":"Blood"},{"key":"e_1_2_11_24_1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jha2.61","article-title":"Low serum albumin is an independent risk factor in elderly patients with aggressive B\u2010cell lymphoma: results from prospective trials of the German high\u2010grade non\u2010Hodgkin's Lymphoma Study Group","volume":"1","author":"Hohloch K","year":"2020","journal-title":"EJHaem"},{"key":"e_1_2_11_25_1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/hon.2233","article-title":"Serum albumin level at diagnosis of diffuse large B\u2010cell lymphoma: an important simple prognostic factor","volume":"34","author":"Bairey O","year":"2016","journal-title":"Hematol Oncol"},{"key":"e_1_2_11_26_1","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2141.2005.05508.x","article-title":"A population\u2010based study of severity of comorbidity among patients with non\u2010Hodgkin's lymphoma: prognostic impact independent of international prognostic index","volume":"129","author":"Janssen\u2010Heijnen MLG","year":"2005","journal-title":"Br J Haematol"},{"key":"e_1_2_11_27_1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright GW","year":"2020","journal-title":"Cancer Cell"},{"key":"e_1_2_11_28_1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy B","year":"2018","journal-title":"Nat Med"},{"key":"e_1_2_11_29_1","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.3324\/haematol.2011.050617","article-title":"The proportion of activated B\u2010cell like subtype among de novo diffuse large B\u2010cell lymphoma increases with age","volume":"96","author":"Mareschal S","year":"2011","journal-title":"Haematologica"},{"key":"e_1_2_11_30_1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/leu.2010.302","article-title":"The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B\u2010cell lymphoma","volume":"25","author":"Ruminy P","year":"2011","journal-title":"Leukemia"},{"key":"e_1_2_11_31_1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1006\/clim.1999.4781","article-title":"Immunoglobulin VH gene expression in human aging","volume":"93","author":"Wang X","year":"1999","journal-title":"Clin Immunol (Orlando, Fla)"},{"key":"e_1_2_11_32_1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO-25-01587","article-title":"Phased variant\u2013supported circulating tumor DNA as a prognostic biomarker after first\u2010line treatment in large B\u2010cell lymphoma: findings from the DIRECT study","volume":"44","author":"Krupka JA","year":"2026","journal-title":"J Clin Oncol"},{"key":"e_1_2_11_33_1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ajh.27151","article-title":"R\u2010miniCHOP versus R\u2010CHOP in elderly patients with diffuse large B\u2010cell lymphoma: a propensity matched population\u2010based study","volume":"99","author":"Al\u2010Sarayfi D","year":"2024","journal-title":"Am J Hematol"},{"key":"e_1_2_11_34_1","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2666-7568(22)00123-4","article-title":"Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75\u2009years or older with de novo diffuse large B\u2010cell lymphoma: a phase 2, single\u2010arm study","volume":"3","author":"Xu P\u2010P","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"e_1_2_11_35_1","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70093_160","article-title":"VERLen: tafasitamab, lenalidomide, plus rituximab in frontline diffuse large B\u2010cell lymphoma patients over 80 y\/o or older, a LYSA phase 2 trial","volume":"43","author":"Tessoulin B","year":"2025","journal-title":"Hematol Oncol"},{"key":"e_1_2_11_36_1","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2023-177588","article-title":"Mosunetuzumab and polatuzumab vedotin demonstrates preliminary efficacy in elderly unfit\/frail patients with previously untreated diffuse large B\u2010cell lymphoma","volume":"142","author":"Olszewski AJ","year":"2023","journal-title":"Blood"},{"key":"e_1_2_11_37_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2025-61","article-title":"Phase II frontline chemolight R\u2010pola\u2010glo trial induces high and durable response rates in elderly and medically unfit\/frail patients with aggressive B\u2010cell lymphoma","volume":"146","author":"Chapuy B","year":"2025","journal-title":"Blood"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70784","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70784","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:47:11Z","timestamp":1790567231000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,27]]},"references-count":36,"alternative-id":["10.1111\/bjh.70784"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70784","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,27]]},"assertion":[{"value":"2026-03-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"bjh.70784"}}